For GSK, Lots Of Drugs In R&D, But Many Are Long-Term

Management highlighted pipeline drugs in respiratory disease, HIV, immuno-oncology and vaccines, but a lot of the drugs in development are early- to mid-stage where the success rate remains uncertain. The meeting isn’t likely to change investor sentiment in the near-term.